Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma

Benedetto Bruno, Roberto Sorasio, Francesca Patriarca, Vittorio Montefusco, Stefano Guidi, Alessandro Busca, Rosanna Scimé, Giuseppe Console, Giuseppe Milone, Giuseppe Marotta, Alida Dominietto, Luisa Giaccone, Marcello Rotta, Michele Falda, Andrea Bacigalupo, Alberto Bosi, Paolo Corradini, Renato Fanin, Simona Pollichieni, Mario Boccadoro

Research output: Contribution to journalArticlepeer-review


Background: Allografting induces long-term molecular remissions and possibly cure in myeloma patients. The development of non-myeloablative conditionings has reduced the transplant-related mortality (TRM) associated with myeloablation and extended the eligible age for transplantation. Moreover, high response rates are reported especially when allografting is preceded by cytoreductive high-dose chemotherapy. We investigated the feasibility of unrelated donor non-myeloablative transplantation as either part of the initial treatment plan or as salvage treatment in heavily pretreated patients. Methods: Twenty-two patients underwent non-myeloablative allografting, 10 as part of their initial treatment and 12 at relapse. Donors were matched for HLA-A, B, C, DRB1 and DQB1 by high-resolution typing. Only one single class I allele disparity was allowed. Conditioning consisted of fludarabine 90 mg/m2 and 2 Gy total body irradiation. Graft-vs.-host disease (GVHD) prophylaxis included cyclosporin and mycophenolate mofetil. Results: All patients except two (91%) readily engrafted. After a median follow-up of 20 (10-30) months, incidences of grade II-IV acute and extensive chronic GVHD were 50% and 61%. Overall response (OR) was 55%, with four (20%) complete and seven (35%) partial remissions. However, in patients allografted up-front OR was 89% whereas in the heavily pretreated group OR was 27% (P = 0.01). Two-year overall and event-free survivals were both 79% in the group transplanted up-front and 27% and 25% among relapsed patients (P = 0.025 and P = 0.006, respectively). Overall, six patients died of TRM and three of disease progression. Conclusions: Unrelated donor non-myeloablative allografting is feasible in myeloma. Disease control appears more pronounced when patients are treated soon after diagnosis.

Original languageEnglish
Pages (from-to)330-337
Number of pages8
JournalEuropean Journal of Haematology
Issue number4
Publication statusPublished - Apr 2007


  • Allogeneic transplantation
  • Engraftment
  • Graft-vs.-host disease
  • Multiple myeloma
  • Non-myeloablative transplantation
  • Unrelated donors

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma'. Together they form a unique fingerprint.

Cite this